Biogen’s Aduhelm was the big one, but there are plenty of other key regulatory decisions still pending this year.
Bristol’s new oral psoriasis option looks much better than Otezla, but competing against injectables could be tricky.
As several big pharma companies drop Parkinson’s projects, attention turns to gene therapies and repurposing diabetes drugs.
New findings for IL-6 blockade in the Recovery trial finally confirm a signal. Can pending pandemic readouts for other mechanisms do the same?
Immunovant and other FcRn-players must hope that a potential safety signal turns out to be indication rather than class specific.
Blockbuster sales are predicted for several projects nearing approval, from Biogen, Argenx, Fibrogen and others.
Early 2021 will see rare diseases dominate for biotech, with Sarepta revealing key data on its gene therapy play.